Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedMar 10, 2026
DataAggregated Company Financials
Companies152
  • 7D-1.1%
  • 3M-6.4%
  • 1Y-5.1%
  • YTD-5.7%

Over the last 7 days, the Healthcare industry has dropped 1.1%, driven by Swedish Orphan Biovitrum declining 3.2%. Meanwhile, Sectra actually outperformed within the industry, gaining 9.4% in the last week. However, the industry is down 5.1% over the past year. As for the next few years, earnings are expected to grow by 25% per annum.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 11 Mar 2026SEK 550.1bSEK 228.5b-SEK 2,954,581,510.7029.2x-186.2x2.4x
Fri, 06 Feb 2026SEK 577.8bSEK 229.0b-SEK 1,987,563,633.8634.6x-290.7x2.5x
Sun, 04 Jan 2026SEK 580.0bSEK 230.4bSEK 3.7b41.3x157.8x2.5x
Tue, 02 Dec 2025SEK 601.0bSEK 230.8bSEK 3.6b42.8x167.5x2.6x
Thu, 30 Oct 2025SEK 612.4bSEK 228.1bSEK 3.5b46.8x177.3x2.7x
Sat, 27 Sep 2025SEK 593.6bSEK 227.1bSEK 6.6b43.5x89.8x2.6x
Mon, 25 Aug 2025SEK 631.7bSEK 227.2bSEK 6.3b49.1x100.4x2.8x
Wed, 23 Jul 2025SEK 624.8bSEK 227.5bSEK 6.7b45.4x93.7x2.7x
Fri, 20 Jun 2025SEK 593.9bSEK 226.7bSEK 5.9b45x101.4x2.6x
Sun, 18 May 2025SEK 610.2bSEK 224.9bSEK 5.6b36.5x108.9x2.7x
Tue, 15 Apr 2025SEK 540.7bSEK 221.8bSEK 5.3b33x102.8x2.4x
Thu, 13 Mar 2025SEK 538.6bSEK 206.1bSEK 4.7b35.4x114.9x2.6x
Sat, 08 Feb 2025SEK 600.9bSEK 220.4bSEK 2.5b42x237.5x2.7x
Mon, 06 Jan 2025SEK 588.1bSEK 202.6b-SEK 2,502,690,753.8640.4x-235x2.9x
Wed, 04 Dec 2024SEK 513.2bSEK 199.5b-SEK 2,880,920,309.9936.7x-178.1x2.6x
Fri, 01 Nov 2024SEK 535.3bSEK 199.9b-SEK 2,884,052,331.0636.6x-185.6x2.7x
Sun, 29 Sep 2024SEK 620.5bSEK 199.9b-SEK 2,815,696,552.4540.2x-220.4x3.1x
Tue, 27 Aug 2024SEK 605.0bSEK 200.0b-SEK 2,345,785,513.6837.5x-257.9x3x
Thu, 25 Jul 2024SEK 602.8bSEK 198.8b-SEK 2,866,260,337.4540.7x-210.3x3x
Sat, 22 Jun 2024SEK 557.3bSEK 195.4b-SEK 3,183,004,397.3135.3x-175.1x2.9x
Mon, 20 May 2024SEK 548.9bSEK 196.3b-SEK 2,920,494,830.6036.3x-188x2.8x
Wed, 17 Apr 2024SEK 520.9bSEK 193.0b-SEK 3,172,218,154.6944.3x-164.2x2.7x
Fri, 15 Mar 2024SEK 526.8bSEK 192.2b-SEK 3,668,152,341.1243.9x-143.6x2.7x
Sun, 11 Feb 2024SEK 509.6bSEK 191.4b-SEK 4,204,413,743.1548.9x-121.2x2.7x
Tue, 09 Jan 2024SEK 544.1bSEK 191.4b-SEK 965,813,732.0048.4x-563.4x2.8x
Thu, 07 Dec 2023SEK 510.8bSEK 190.4b-SEK 1,084,900,302.0050.3x-470.9x2.7x
Sat, 04 Nov 2023SEK 458.1bSEK 189.3b-SEK 1,100,030,806.0040.3x-416.4x2.4x
Mon, 02 Oct 2023SEK 450.7bSEK 185.0b-SEK 2,032,472,591.0035.4x-221.8x2.4x
Wed, 30 Aug 2023SEK 465.7bSEK 185.7b-SEK 1,768,733,347.0038.1x-263.3x2.5x
Fri, 28 Jul 2023SEK 477.8bSEK 183.4b-SEK 953,450,694.0040.9x-501.2x2.6x
Sun, 25 Jun 2023SEK 483.3bSEK 179.1b-SEK 798,027,738.0043.6x-605.6x2.7x
Tue, 23 May 2023SEK 523.4bSEK 177.4b-SEK 840,009,313.0043.4x-623.1x2.9x
Thu, 20 Apr 2023SEK 507.9bSEK 172.5b-SEK 1,420,459,366.0034.4x-357.5x2.9x
Sat, 18 Mar 2023SEK 482.6bSEK 172.2b-SEK 1,415,577,844.0035.9x-340.9x2.8x
Price to Earnings Ratio

-340.9x


Total Market Cap: SEK 482.6bTotal Earnings: -SEK 1,415,577,844.00Total Revenue: SEK 172.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -167x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market-4.91%
Healthcare-1.07%
Healthtech8.03%
Healthcare Services0.037%
Pharma-1.20%
Medical Equipment-1.74%
Biotech-2.47%
Life Sciences-5.12%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 115x.
    • Analysts are expecting annual earnings growth of 21.9%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SECT B SectraSEK 224.0020.4%
+SEK 7.3b		1.7%PE80.3x
BIOA B BioArcticSEK 320.8010.6%
+SEK 2.7b		59.0%PE27.8x
SOBI Swedish Orphan BiovitrumSEK 388.601.6%
+SEK 2.1b		37.7%PE281x
ASKER Asker Healthcare GroupSEK 64.718.8%
+SEK 2.0b		n/aPE53.8x
EKTA B ElektaSEK 60.659.2%
+SEK 1.9b		8.3%PS1.4x

Latest News

AMBEA
SEK 135.70
Ambea
7D
5.3%
1Y
33.8%
SECT B
SEK 224.00
Sectra
7D
20.4%
1Y
1.7%
ORX
SEK 24.50
Orexo
7D
-7.4%
1Y
62.9%
SOBI
SEK 388.60
Swedish Orphan Biovitrum
7D
1.6%
1Y
37.7%

SOBI: Kidney And Sepsis Advances Will Support A More Upbeat Outlook

The analyst fair value estimate for Swedish Orphan Biovitrum has been adjusted from SEK 416 to SEK 424, reflecting recent price target increases to SEK 470 and SEK 500, as well as updated analyst views on revenue growth, margins and future P/E assumptions. Analyst Commentary Recent Street research on Swedish Orphan Biovitrum presents a mix of optimism and caution around the shares, which helps frame the updated fair value estimate of SEK 424.
EKTA B
SEK 60.65
Elekta
7D
9.2%
1Y
8.3%
HNSA
SEK 30.32
Hansa Biopharma
7D
-1.7%
1Y
37.6%
VIMIAN
SEK 25.96
Vimian Group
7D
3.8%
1Y
-27.6%

VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects

Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.
ALIF B
SEK 141.20
AddLife
7D
-2.8%
1Y
-2.8%
CAMX
SEK 482.00
Camurus
7D
1.7%
1Y
-14.5%

CAMX: Upcoming US And EU Launches Will Drive Future Upside Potential

Analysts have reset their price target on Camurus to SEK 930 from SEK 1,102, reflecting updated views on slightly higher forecast revenue growth, a modestly lower projected profit margin and a reduced future P/E multiple. What's in the News Camurus issued earnings guidance for 2026, expecting revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).
PAX
SEK 47.00
Paxman
7D
-8.9%
1Y
-24.4%
CURAS
DKK 15.65
Curasight
7D
-8.2%
1Y
105.4%
IMP A SDB
SEK 41.60
Implantica
7D
-4.1%
1Y
24.9%
GETI B
SEK 194.95
Getinge
7D
-0.1%
1Y
-8.4%

GETI B: Modest Dividend Uplift Will Not Offset Rich P/E Multiple

Narrative update on Getinge Analysts have slightly adjusted their view on Getinge, with the updated price target now set at SEK 170.97. This reflects modest tweaks to assumptions around discount rate, revenue growth, profit margin and future P/E.
BIOA B
SEK 320.80
BioArctic
7D
10.6%
1Y
59.0%
ASKER
SEK 64.71
Asker Healthcare Group
7D
8.8%
1Y
n/a
VICO
SEK 10.26
Vicore Pharma Holding
7D
-1.7%
1Y
42.3%